Mortality and clinical outcomes
| SGA static SpO2 group (n=22) | SGA graded SpO2 group (n=35) | P value(a) | AGA static SpO2 group (n=245) | AGA graded SpO2 group (n=185) | P value(a) | |
|---|---|---|---|---|---|---|
| Birth weight (grams) median (25–75th percentile) | 545 (480–608) | 505 (476–545) | 0.20 | 760 (677–853) | 755 (660–855) | 0.79 |
| GA (weeks) median (25–75th percentile) | 26 (25–26) | 26 (25–27) | 0.48 | 26 (25–26.5) | 25.8 (24.8–26.4) | 0.48 |
| Antenatal steroids n (%) | 15/22 (68.2) | 32/35 (91.5) | 0.02 | 173/241 (71.8) | 150/183 (82.0) | 0.01 |
| Chorioamnionitis n (%) | 3/22 (13.6) | 4/35 (11.4) (b) | 1.00 | 54/242 (22.3) | 50/183 (27.3) | 0.23 |
| Death n (%) | 6/20 (30) | 8/35 (22) | 0.55 | 22/223 (9.9) | 14/182 (7.7) | 0.44 |
| Severe ROP n (%) | 10/18 ( 55.6) | 13/29 (44.8) | 0.47 | 102/214 (47.7) | 29/168 (17.3) | 0.000 |
| Laser Rx for ROP n (%) | 7/18 (38.9) | 7/29 (24.1) | 0.28 | 74/214 (34.6) | 32/169 (18.9) | 0.001 |
| Bronchopulmonary dysplasia n (%) | 10/17 (58.8) | 16/29 (55.2) | 0.80 | 74/211 (35) | 39/170 (22.3) | 0.01 |
| Severe Intraventricular haemorrhage n (%) | 2/16 (12.5) | 6/35 (17.1) | 0.67 | 54/217 (24.9) | 27/184 (14.7) | 0.01 |
| Patent ductus arteriosus n (%) | 17/22 (77.3) | 28/35 (80) | 0.80 | 196/245 (80) | 152/185 (82.2) | 0.57 |
| Necrotizing enterocolitis n (%) | 2/22 (9.1) | 3/34 (11.8) (b) | 1.00 | 35/245 (14.3) | 12/184 (6.5) | 0.01 |
a: Chi-square tests and b: Fischer exact test